CNS Pharmaceuticals, Inc. (CNSP)Healthcare | Biotechnology | Houston, United States | NasdaqCM
5.52 USD
+0.01
(0.100%)
⇧
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 5.75 +0.23 (4.112%) ⇧ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 5:42 a.m. EDT
The investment case here is structurally broken. Over the last five years, the stock has erased nearly 100% of its value, with every single year showing a massive decline, including a catastrophic drop in 2024 where the price collapsed from hundreds of dollars to under $10. This isn't a temporary setback; it is a multi-year structural deterioration that suggests the market has permanently reassessed the business quality downward. While recent headlines celebrate a $22.5 million capital raise and a strategic pivot to new drug targets, these are desperate measures for a company with no earnings, negative free cash flow, and a balance sheet that cannot sustain operations without further dilution. The lack of any dividend history confirms the company is burning cash rather than returning value. For the short term, the recent price bounce off the lows offers a fleeting, low-conviction opportunity, but the overwhelming weight of the long-term data—five consecutive years of destruction—makes this a clear avoid. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.082353 |
| AutoETS | 0.085010 |
| AutoARIMA | 0.085013 |
| AutoTheta | 0.380743 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 31% |
| H-stat | 0.43 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.602 |
| Excess Kurtosis | -0.45 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 8,071,437 |
| Forward P/E | -14.16 |
| Beta | 0.98 |
| Website | https://cnspharma.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.11728001 |
| Address1 | 2,100 West Loop South |
| Address2 | Suite 900 |
| All Time High | 5,121,000.0 |
| All Time Low | 1.9 |
| Ask | 7.36 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 11,230 |
| Average Daily Volume3 Month | 11,675 |
| Average Volume | 11,675 |
| Average Volume10Days | 11,230 |
| Beta | 0.98 |
| Bid | 4.11 |
| Bid Size | 2 |
| Book Value | 12.453 |
| City | Houston |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 5.5229 |
| Current Ratio | 5.865 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 5.79 |
| Day Low | 5.4774 |
| Display Name | CNS Pharmaceuticals |
| Earnings Timestamp End | 1,755,547,200 |
| Earnings Timestamp Start | 1,755,028,800 |
| Ebitda | -16,899,640 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.705 |
| Enterprise Value | -11,913,563 |
| Eps Forward | -0.39 |
| Eps Trailing Twelve Months | -15.39 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 5.14786 |
| Fifty Day Average Change | 0.37504005 |
| Fifty Day Average Change Percent | 0.07285359 |
| Fifty Two Week Change Percent | -11.728001 |
| Fifty Two Week High | 10.588 |
| Fifty Two Week High Change | -5.0651 |
| Fifty Two Week High Change Percent | -0.4783812 |
| Fifty Two Week Low | 1.9 |
| Fifty Two Week Low Change | 3.6229 |
| Fifty Two Week Low Change Percent | 1.9067895 |
| Fifty Two Week Range | 1.9 - 10.588 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,573,223,400,000 |
| Float Shares | 1,316,502 |
| Forward Eps | -0.39 |
| Forward P E | -14.161283 |
| Free Cashflow | -7,938,823 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 8 |
| Fullday Change | 0.00550032 |
| Fullday Change Percent | 0.0996904 |
| Fullday Price | 5.75 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00949 |
| Held Percent Institutions | 0.21254 |
| Implied Shares Outstanding | 1,461,449 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,753,142,400 |
| Last Split Factor | 1:12 |
| Long Business Summary | CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors. The company was incorporated in 2017 and is headquartered in Houston, Texas. |
| Long Name | CNS Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 8,071,437 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_555951193 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -16,699,564 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 8,063,398 |
| Number Of Analyst Opinions | 1 |
| Open | 5.7 |
| Operating Cashflow | -13,413,107 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 800 946 9185 |
| Post Market Change | 0.2270999 |
| Post Market Change Percent | 4.111968 |
| Post Market Price | 5.75 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 5.5174 |
| Price Hint | 2 |
| Price To Book | 0.44349957 |
| Profit Margins | 0.0 |
| Quick Ratio | 5.346 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.0055003166 |
| Regular Market Change Percent | 0.09969038 |
| Regular Market Day High | 5.79 |
| Regular Market Day Low | 5.4774 |
| Regular Market Day Range | 5.4774 - 5.79 |
| Regular Market Open | 5.7 |
| Regular Market Previous Close | 5.5174 |
| Regular Market Price | 5.5229 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 3,704 |
| Return On Assets | -0.58013 |
| Return On Equity | -1.06621 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 1,461,449 |
| Shares Percent Shares Out | 0.0086 |
| Shares Short | 12,595 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 15,780 |
| Short Name | CNS Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.0087 |
| Short Ratio | 1.81 |
| Source Interval | 15 |
| State | TX |
| Symbol | CNSP |
| Target High Price | 10.0 |
| Target Low Price | 10.0 |
| Target Mean Price | 10.0 |
| Target Median Price | 10.0 |
| Total Cash | 19,985,000 |
| Total Cash Per Share | 13.675 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -15.39 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.857685 |
| Two Hundred Day Average Change | 0.665215 |
| Two Hundred Day Average Change Percent | 0.13694075 |
| Type Disp | Equity |
| Volume | 3,704 |
| Website | https://cnspharma.com |
| Zip | 77,027 |